A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL)
Sharman, Jeff P., Liberati, Anna Marina, Ishizawa, Kenichi, Khan, Tahira, Robbins, Jeffery, Alcasid, Ann, Rosenberg, Julie Ann, Aurer, Igor
Published in BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy (01.04.2020)
Published in BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy (01.04.2020)
Get full text
Journal Article
A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL)
Sharman, Jeff, Liberati, Anna Marina, Santucci Silva, Rodrigo, Aurer, Igor, Robbins, Jeffery, Rosenberg, Julie Ann, Khan, Tahira, Alcasid, Ann
Published in Blood (29.11.2018)
Published in Blood (29.11.2018)
Get full text
Journal Article